Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Replimune Group, Inc. on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding deficiencies in its drug studies that were likely to cause the FDA to reject its Biologics License Application (BLA). Investors are encouraged to join the case by October 5, 2026, to potentially recover damages.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Pomerantz LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) following a significant drop in its stock price. The lawsuit stems from the FDA's rejection of Replimune's Biologics License Application for RP1, citing deficiencies in study design and insufficient evidence of effectiveness. Investors who purchased Replimune securities during the Class Period have until October 5, 2026, to seek lead plaintiff status.
Press Release: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group, Inc. announced inducement grants of stock options and restricted stock units (RSUs) to newly hired employees. These grants were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment and were approved by the Compensation Committee of Replimune's Board of Directors. The options have a ten-year term and a per-share exercise price equal to the closing price of Replimune’s common stock on the grant date, vesting over four years.
Replimune CFO Emily Hill sells $132,175 in stock for tax obligations
Replimune Group, Inc.'s CFO, Emily Hill, sold 9,256 shares of company stock worth $132,175. This transaction was for tax withholding obligations related to vested Restricted Stock Units and was not a discretionary sale. Following the sale, Ms. Hill directly holds 215,852 shares, amidst recent positive news for Replimune including FDA approval for a cancer treatment and analyst upgrades.
Replimune CFO Emily Hill sells $132,175 in stock for tax obligations
Replimune CFO Emily Hill sold 9,256 shares of company stock worth $132,175 on August 17, 2026, to cover tax withholding obligations from vesting Restricted Stock Units. This was not a discretionary sale but a "sell to cover" transaction. Following the sale, Hill directly holds 215,852 shares, amidst recent positive analyst upgrades and FDA accelerated approval for Replimune's cancer treatment.
Replimune Group (NASDAQ:REPL) CFO Sells $132,175.68 in Stock
Replimune Group's CFO, Emily Luisa Hill, sold 9,256 shares worth $132,175.68 to cover tax obligations from vested equity awards, retaining 215,852 shares. The company's stock, REPL, traded at $14.81, near its 12-month high, despite missing quarterly EPS estimates. While analysts have a "Moderate Buy" consensus, a securities lawsuit regarding FDA concerns adds uncertainty.
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders
Glancy Prongay Wolke & Rotter LLP is reminding investors of Replimune Group, Inc. (REPL) who suffered losses to consider filing a lead plaintiff motion by October 5, 2026, in a securities fraud class action lawsuit. The lawsuit alleges that Replimune made misleading statements regarding its Biologics License Application (BLA) for RP1, which the FDA ultimately rejected due to deficiencies in study design and data presentation. This rejection led to a significant drop in the company's share price.
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group, Inc. announced inducement equity awards to Michelle DiNapoli, the Company's Chief Commercial Officer. These awards include a non-qualified stock option for 150,000 shares and restricted stock units for 100,000 shares. The grants were approved under Nasdaq Listing Rule 5635(c)(4) and are intended to align with the company's 2018 Equity Incentive Plan terms.
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased shares between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false or misleading statements regarding its RP1 biologics license resubmission and the sufficiency of its clinical trial data. Investors are encouraged to contact the firm by the October 5, 2026, lead plaintiff deadline if they wish to recover investment losses.
Replimune Soars Over 120% as FDA Panel Backs Melanoma Therapy Ahead of August Decision
Shares of Replimune Group (REPL) surged over 120% after an FDA advisory committee voted 10 to 3 that its melanoma therapy, RP1, showed clinically meaningful efficacy. This vote reverses previous FDA rejections and sets the stage for a final regulatory decision expected by August 2, 2026. Analysts have reacted positively, with Cantor Fitzgerald upgrading the stock, and the heavily shorted company anticipates high volatility.
Shareholders of Replimune Group urged to join class action over alleged misleading FDA data disclosures.
The Gross Law Firm has initiated a class action lawsuit against Replimune Group, Inc. for shareholders who purchased stock between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false or misleading statements regarding its FDA Biologics License Application, failing to address FDA concerns and relying on limited early data. Shareholders have until October 5, 2026, to register for participation or seek lead plaintiff status.
Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL
Quantinno Capital Management LP significantly increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 782.7% in the first quarter, now owning 108,477 shares valued at $830,000. Institutional investors collectively hold 92.53% of the company, and analyst sentiment has improved, leading to a "Moderate Buy" rating with an average price target of $11.86. Despite recent insider stock sales to cover tax obligations, the company's stock opened near its 12-month high, although it reported a quarterly loss slightly below consensus estimates.
Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL
Robbins LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune misled investors regarding the efficacy of its lead product candidate, RP1, leading to a significant drop in stock price after the FDA rejected its Biologics License Application. Investors who suffered losses are urged to contact Robbins LLP by the October 5, 2026, deadline to learn about their rights.
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged federal securities law violations. The lawsuit claims Replimune made misleading statements regarding deficiencies in its BLA submission to the FDA, which were likely to cause rejection. Investors who purchased Replimune securities between October 20, 2025, and April 10, 2026, are encouraged to join the case, with a lead plaintiff deadline of October 5, 2026.
REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP is reminding investors of Replimune Group, Inc. (NASDAQ: REPL) about an upcoming securities class action deadline. The lawsuit is filed on behalf of shareholders who purchased securities between October 20, 2025, and April 10, 2026, following a significant 84% stock decline after the FDA rejected Replimune's RP1 biologics license application. Investors have until October 5, 2026, to seek lead plaintiff status in the case.
REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP is alerting investors of Replimune Group, Inc. (NASDAQ: REPL) about a pending securities class action lawsuit following a significant drop in stock price. The lawsuit stems from the FDA's rejection of Replimune's RP1 biologics license application, which led to an 84% cumulative decline in shares. Investors who purchased securities between October 20, 2025, and April 10, 2026, have until October 5, 2026, to seek lead plaintiff status.
Replimune Group (REPL): Ridgeback Capital now reports 3.5% ownership stake
Ridgeback Capital entities have updated their ownership stake in Replimune Group (REPL) via an amended Schedule 13G filing. The filing indicates that Ridgeback Capital now beneficially owns 2,912,373 shares of common stock, representing 3.5% of the outstanding shares as of August 13, 2026. This is a decrease from their previously reported 8.7% ownership, which consisted of 7,310,656 shares as of June 25, 2026.
Replimune (NASDAQ: REPL) secures FDA accelerated approval and raises $141M
Replimune Group, Inc. reported a Q1 net loss of $69.8 million but secured FDA accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for advanced cutaneous melanoma. The company also raised $141.0 million in net proceeds from an August 2026 equity offering, extending its cash runway for more than 12 months, including for TUDRIQEV's commercialization. The approval validates Replimune's oncolytic immunotherapy platform, despite ongoing unprofitability and a required confirmatory trial.
Replimune Group stock may move 5.6% on earnings release
Replimune Group Inc. (NASDAQ:REPL) stock is predicted to move 5.6% following its earnings report on August 21, according to options data compiled by Bloomberg. The company's past earnings announcements have shown varied actual price movements compared to implied options changes, with the stock exceeding implied moves in three out of eight previous releases. Investors are anticipating the upcoming announcement for further insights into the company's performance.
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Replimune Group, Inc. (NASDAQ: REPL) regarding a securities class action lawsuit. Shareholders who purchased REPL shares between October 20, 2025, and April 10, 2026, are encouraged to contact the firm, as the complaint alleges the company made false or misleading statements regarding its BLA submission to the FDA. The deadline to seek lead plaintiff appointment in this case is October 5, 2026.
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders
Glancy Prongay Wolke & Rotter LLP is reminding investors of Replimune Group, Inc. (REPL) who suffered losses between October 20, 2025, and April 10, 2026, about an upcoming October 5, 2026 deadline to file a lead plaintiff motion in a securities fraud lawsuit. The lawsuit alleges that Replimune made misleading statements regarding its Biologics License Application (BLA) for RP1, which the FDA ultimately rejected due to unaddressed study design concerns and insufficient data. This rejection led to a significant drop in Replimune's share price.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Replimune Group Inc. (REPL) after the FDA deemed the company's lead trial for its skin cancer drug RP1 "not interpretable," causing a significant drop in stock price. The firm is encouraging shareholders who purchased Replimune securities to connect to learn more about the investigation into potential claims. The investigation seeks to recover investor capital and ensure corporate accountability.
Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results
Replimune Group (NASDAQ:REPL) reported a Q1 loss of $0.72 per share, missing analyst estimates. Despite the earnings miss and ongoing litigation, the company's shares fell by 1.4% to $14.97, and it expects to launch TUDRIQEV™ (RP1) for advanced melanoma within 60 days following FDA accelerated approval. Replimune also completed a $150 million financing round to support the product launch and confirmatory trial, while analysts maintain a "Moderate Buy" rating with an average price target of $11.86.
REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on
Kirby McInerney LLP has filed a securities fraud class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding the Biologics License Application (BLA) for its lead product candidate, RP1, which was ultimately rejected by the FDA. Investors who suffered losses are encouraged to contact Kirby McInerney LLP by October 5, 2026, to discuss their rights and apply for lead plaintiff appointment.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group Inc. (NASDAQ: REPL) after the FDA deemed a key study for their drug RP1 as "not interpretable," causing a significant drop in stock price. The firm is encouraging affected shareholders to join their investigation, operating on a contingency fee basis.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL
SueWallSt is reminding shareholders of Replimune Group, Inc. (REPL) about a lead plaintiff deadline of October 5, 2026, in a securities class action lawsuit. The lawsuit alleges that Replimune made misleading statements regarding the FDA's review of its RP1 resubmission, leading to an 84% stock price decline after the FDA rejected the biologics license application. Investors who purchased shares between October 20, 2025, and April 10, 2026, may be eligible to recover losses.
Replimune Group Stock Short Interest Rises to 57.95%
Replimune Group Inc. (NASDAQ:REPL) saw a significant increase in short interest during July, rising 57.95% to 5.25 million shares. This represents 14.7% of the company's shares outstanding, indicating a growing bearish sentiment among investors. The average daily trading volume suggests it would take approximately 11.5 days to cover these short positions.
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Levi & Korsinsky, LLP has issued a shareholder alert for Replimune Group, Inc. (NASDAQ: REPL) investors who purchased securities between October 20, 2025, and April 10, 2026. The class action lawsuit alleges that the company made misleading statements regarding the FDA's review of its RP1 biologics license resubmission, leading to an approximate 84% stock price decline. Investors have until October 5, 2026, to seek lead plaintiff status in the lawsuit filed in the United States District Court for the District of Massachusetts.
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Levi & Korsinsky, LLP has issued a shareholder alert regarding a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). The lawsuit alleges that Replimune misled investors between October 20, 2025, and April 10, 2026, by claiming its RP1 FDA resubmission was on track despite unresolved study-design concerns. Following the FDA's rejection of the Biologics License Application due to these unaddressed concerns, Replimune's shares dropped significantly, and investors have until October 5, 2026, to seek lead plaintiff status.
Replimune Group (NASDAQ:REPL) CAO Sells 7,632 Shares
Replimune Group's CAO, Andrew Schwendenman, sold 7,632 shares of the company's stock for approximately $98,987 to cover tax-withholding obligations. Despite this insider sale, Replimune has seen positive analyst sentiment and recently priced a $150 million public offering for its oncology pipeline. However, the company faces a class-action lawsuit concerning its RP1 product and recently missed analyst earnings estimates.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Pomerantz LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who suffered losses. The lawsuit alleges securities fraud or other unlawful business practices following the FDA's rejection of Replimune's Biologics License Application (BLA) for RP1 in combination with nivolumab due to deficiencies in clinical trials. Investors have until October 5, 2026, to seek appointment as Lead Plaintiff.
Replimune Group (NASDAQ:REPL) Insider Sells 11,447 Shares of Stock
Konstantinos Xynos, an insider at Replimune Group (NASDAQ:REPL), sold 11,447 shares of the company's stock for approximately $148,468 to cover tax obligations. Despite the sale, Replimune's stock has performed strongly, nearing its 52-week high, although the company reported a larger-than-expected quarterly loss. Institutional ownership remains high, and while some analysts have upgraded the stock, ongoing securities class-action allegations present a legal challenge.
Replimune group CEO Sushil Patel sells $510,252 in stock
Replimune Group CEO Sushil Patel sold 39,341 shares of the company's common stock for $510,252 on August 10, 2026, to cover tax withholding obligations. This sale was not discretionary and was tied to performance-based restricted stock units. The company has recently received FDA accelerated approval for its cancer treatment Tudriqev, leading to positive analyst upgrades and a significant stock appreciation.
What happened at FDA? Replimune approval raises questions
The article discusses the accelerated approval of Replimune Group Inc.'s biologic, RP1, by the FDA for advanced melanoma, following a 10:3 advisory committee vote. This approval comes after a protracted process involving two previous rejections, political pressure, and significant debate among experts about the drug's efficacy and the FDA's decision-making process. The authors express confusion over the FDA's unpredictable actions and the challenges of assessing the drug based on messy, single-arm trial data.
REPL Class Action Reminder - Robbins LLP Reminds Investors
Robbins LLP is reminding investors of a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). The lawsuit alleges that Replimune misled investors about the efficacy and viability of its lead product candidate RP1, after the FDA rejected its Biologics License Application due to study design concerns and insufficient data. Investors who purchased REPL securities between October 20, 2025, and April 10, 2026, may have legal rights and are encouraged to contact Robbins LLP to learn more about participating in the class action.
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL
Levi & Korsinsky, LLP is alerting investors of Replimune Group, Inc. (NASDAQ: REPL) about a pending securities class action lawsuit. The lawsuit, brought on behalf of shareholders who purchased securities between October 20, 2025, and April 10, 2026, alleges that the company and its CEO and CFO made materially false or misleading statements regarding the status of its RP1 biologics license resubmission and undisclosed FDA study-design concerns. Investors who suffered losses during this period have until October 5, 2026, to apply for lead plaintiff status.
Replimune Group Stock Short Interest Rises to 57.95%
Short interest in Replimune Group (REPL) increased to 57.95% of its float by July 31st, totaling 27,540,626 shares, which represents a 16.43% rise from July 15th. It would take an estimated 3.26 days for short sellers to cover their positions at current trading volumes. While 129 institutional investors added REPL shares in the most recent quarter, insider trading activity shows 8 sales and no purchases over the past six months, and analysts have issued only "Sell" or "Underweight" ratings with a median price target of $2.0.
REPL INVESTOR NOTICE: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for purchasers of securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its Biologics License Application (BLA) for RP1, which was subsequently rejected by the FDA due to unaddressed study design concerns and insufficient data. Investors with substantial losses have until October 5, 2026, to seek appointment as lead plaintiff.
Baker Bros. Advisors (NASDAQ: REPL) details 11.8% stake and warrant buys
Baker Bros. Advisors and related entities have filed an amended beneficial ownership report for Replimune Group, Inc. common stock, revealing a beneficial ownership of 11,075,336 shares, which represents an 11.8% stake. The report also details Baker Bros.' purchase of all 2,736,340 pre-funded warrants in a recent public offering for approximately $33 million, though these warrants are currently unexercisable due to beneficial ownership caps. Additionally, Replimune director Michael Goller is subject to a lock-up agreement until September 24, 2026, which does not apply to Baker Bros. or its advised funds.
Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced that investors who suffered losses with Replimune Group, Inc. (REPL) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that between October 20, 2025, and April 10, 2026, Replimune made false or misleading statements and failed to disclose material adverse facts regarding the company's business, operations, and prospects, specifically concerning deficiencies in their BLA submissions to the FDA. Investors who purchased shares during this period are encouraged to contact the firm before the October 5, 2026, lead plaintiff deadline.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
Pomerantz LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged securities fraud. The lawsuit comes after the FDA rejected Replimune's Biologics License Application for RP1, citing several deficiencies in its studies, leading to significant drops in the company's stock price. Investors who purchased Replimune securities during the Class Period have until October 5, 2026, to seek appointment as Lead Plaintiff.
Replimune Group, Inc. (REPL) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Replimune Group, Inc. (REPL) stock, including its current price, news headlines, and performance data. The stock is listed on NasdaqGS and shows recent fluctuations based on FDA decisions regarding its drug candidates. News articles detail both positive developments, such as FDA panel backing and resubmission plans for melanoma drugs, and setbacks like FDA rejections.
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged securities fraud. The lawsuit, covering the period from October 20, 2025, to April 10, 2026, claims Replimune made misleading statements by failing to disclose FDA concerns regarding its Biologics License Application (BLA) for the RP1-104 study. Investors who suffered losses during this period are encouraged to contact SBS by the October 5, 2026 deadline to potentially serve as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its business operations and prospects, specifically concerning study design deficiencies and an inadequate BLA submission to the FDA. Investors who suffered losses are encouraged to join the case by October 5, 2026.
Replimune Group stock hits 52-week high at 13.92 USD
Replimune Group stock has reached a 52-week high of $13.92, driven by a 128% one-year return and recent FDA accelerated approval for its cancer treatment TUDRIQEV. While analysts have upgraded the stock and increased price targets, InvestingPro suggests the shares may be overvalued, and the company is quickly burning cash with no anticipated profitability this year.
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
Replimune Group's stock has surged nearly 223% in the past three months, primarily due to the FDA's accelerated approval of its lead oncolytic immunotherapy, RP1 (Tudriqev), for advanced melanoma. This approval, in combination with Bristol Myers' Opdivo, marks a significant commercial milestone for Replimune after a lengthy regulatory process. The company is also advancing other pipeline candidates like RP1 for skin cancers and RP2 for metastatic uveal melanoma and hepatocellular carcinoma.
Replimune prices $150M underwritten offering of common stock and pre-funded warrants
Replimune (REPL) has priced an underwritten offering to raise approximately $150.0 million in gross proceeds. The offering includes 9,701,490 shares of common stock and pre-funded warrants for 2,736,340 shares, priced at $12.06 per share. Net proceeds are estimated to be around $140.5 million after deductions, with securities expected to be delivered on or about August 11, 2026.
Replimune in the spotlight: Earnings loom days after FDA approval
Replimune Group Inc. is set to report its fiscal fourth-quarter earnings, marking its first financial update since receiving FDA approval for its melanoma therapy, Tudriqev. Despite the regulatory success, analysts have significantly lowered EPS estimates, though most still rate the stock a "Buy" with substantial upside. Investors are closely watching for details on commercial readiness, launch timelines, revenue guidance, and progress on the confirmatory Phase 3 IGNYTE-3 trial.
Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment
The FDA has granted accelerated approval to Replimune Group Inc. for its novel oncolytic immunotherapy, Tudriqev, for advanced cutaneous melanoma. This approval comes after previous rejections and relies on promising clinical trial results from the IGNYTE trial, which showed a 24.2% objective response rate when Tudriqev was administered with nivolumab. The company will need to conduct additional confirmatory studies to maintain the indication.
Law Offices of Frank R. Cruz Encourages Replimune Group, Inc. (REPL) Shareholders To Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz has filed a class action lawsuit against Replimune Group, Inc. (REPL) on behalf of shareholders who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made materially false and misleading statements regarding its Biologics License Application (BLA) for RP1, which was rejected by the FDA due to study design deficiencies. Shareholders are encouraged to inquire about the securities fraud class action and file a lead plaintiff motion by October 5, 2026.
